Overview

Intestinal Microbiota Transplantation, Radiochemotherapy and Sintilimab in Localized Advanced Colon Cancer

Status:
ENROLLING_BY_INVITATION

Trial end date:
2028-08-01

Target enrollment:

Participant gender:

Summary

The standard treatment for locally advanced rectal cancer is neoadjuvant chemoradiotherapy followed by total mesorectal excision. While Immune checkpoint inhibitors are promising in the treatment of various cancers, the combination of radiotherapy and immunotherapy still lacks high-level evidence-based medicine, and the efficacy is still limited in rectal cancer. Thus, we designed a study on the efficacy and safety of intestinal microbiota transplantation combined with synchronous radiochemotherapy and immune checkpoint inhibitor xindilimab neoadjuvant therapy for locally advanced rectal cancer.

Phase:

PHASE4

Details

Lead Sponsor:

First Affiliated Hospital of Ningbo University

Treatments:

Drug Therapy
Gastrointestinal Microbiome
sintilimab